FDA seeks more information on Schering-Plough's Saphris

01/14/2009 | Star-Ledger (Newark, N.J.), The · Forbes

U.S. regulators requested more data from studies of Saphris, Schering-Plough's drug candidate for schizophrenia and bipolar disorder in adults. The FDA also made labeling recommendations but did not require additional trials. Schering said it will respond to the agency's concerns at the end of March.

View Full Article in:

Star-Ledger (Newark, N.J.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD